A platform for glycoengineering a polyvalent pneumococcal bioconjugate vaccine using E. coli as a host
Bioconjugation is a promising process to manufacture conjugate vaccines, but currently employed enzymes cannot generate the full spectrum of bacterial glycoproteins. Here, the authors use an O-linking oligosaccharyltransferase to generate a polyvalent pneumococcal bioconjugate vaccine with polysacch...
Enregistré dans:
Auteurs principaux: | Christian M. Harding, Mohamed A. Nasr, Nichollas E. Scott, Guillaume Goyette-Desjardins, Harald Nothaft, Anne E. Mayer, Sthefany M. Chavez, Jeremy P. Huynh, Rachel L. Kinsella, Christine M. Szymanski, Christina L. Stallings, Mariela Segura, Mario F. Feldman |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Nature Portfolio
2019
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/def4f3d9176a44dbb8129ca597b1866c |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Direct quality control of glycoengineered erythropoietin variants
par: Tomislav Čaval, et autres
Publié: (2018) -
Cytoplasmic glycoengineering enables biosynthesis of nanoscale glycoprotein assemblies
par: Hanne L. P. Tytgat, et autres
Publié: (2019) -
A flow platform for degradation-free CuAAC bioconjugation
par: Marine Z. C. Hatit, et autres
Publié: (2018) -
Glycoengineering of EphA4 Fc leads to a unique, long-acting and broad spectrum, Eph receptor therapeutic antagonist
par: Cassandra L. Pegg, et autres
Publié: (2017) -
EXAMINATION AND TESTING OF EXPERIMENTAL-PRODUCTION SERIES OF POLYVALENT BRUCELLOSIS SERUM
par: N. M. Andreevskaya, et autres
Publié: (2012)